Combining accomplished pharmaceutical scientists and cutting edge academicians focused on oncology drug

discovery and the chemical and structural biology of chromatin regulation.

 

A Small molecule MerTK inhibitor UNC569 is shown in green in the active site of the MERTK protein.

“The Center for Integrative Chemical Biology and Drug Discovery (CICBDD) combines accomplished pharmaceutical scientists and cutting edge academicians focused on oncology drug discovery and the chemical and structural biology of chromatin regulation. The first clinical candidate from the Center will enter Phase 1 trials in Spring 2018 and is focused on activating the innate immune system in solid tumors and leukemia. The Center’s chromatin science is centered on methyl-lysine as a posttranslational modification and the protein-protein interactions that it facilitates.  The first chemical probes for methyl-lysine reader proteins were discovered in the CICBDD and will be used to validate novel interventions in cancer and other diseases.”

 

 

CHEMICAL BIOLOGY CONSORTIUM
The center provides leadership of the North Carolina Comprehensive Chemical Biology Center, a member of NCI’s Chemical Biology Consortium.
ACADEMIC DRUG DISCOVERY CONSORTIUM
The Academic Drug Discovery Consortium is a non-profit formed in 2012 by 5 prominent academic drug discovery centers, including the CICBDD. For more click here.

 

 

 

 

 


 

Back to Top